Literature DB >> 10822237

Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease.

D G Harwood1, W W Barker, R L Ownby, R Duara.   

Abstract

OBJECTIVE: This cross-sectional study examined the relationship of behavioral and psychological symptoms to cognitive and functional impairment in Alzheimer's disease (AD).
DESIGN: One hundred and fourteen patients were evaluated consecutively at a university-affiliated outpatient memory disorders clinic and diagnosed with possible or probable Alzheimer's disease (AD) according to NINCDS-ADRDA criteria. Subjects were assessed with the Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD), Revised Memory and Behavior Problem Checklist (RMBPC), Blessed Dementia Scale (BDS), and Mini-Mental State Examination (MMSE).
RESULTS: Several symptoms of behavioral pathology showed associations with MMSE scores, including activity disturbances, delusions, and hallucinations. After controlling for the variance associated with the MMSE, activity disturbances, diurnal disturbances, delusions, and hallucinations were linked with BDS scores.
CONCLUSIONS: The results suggest that some non-cognitive symptoms may be related to the neurobiologic mechanisms underlying the increased cognitive dysfunction in AD. Specific symptoms of behavioral pathology may also impact a patient's ability to perform important self-maintenance behaviors. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10822237     DOI: 10.1002/(sici)1099-1166(200005)15:5<393::aid-gps120>3.0.co;2-o

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  19 in total

1.  Executive dysfunction in Alzheimer disease.

Authors:  Margaret M Swanberg; Rochelle E Tractenberg; Richard Mohs; Leon J Thal; Jeffrey L Cummings
Journal:  Arch Neurol       Date:  2004-04

2.  Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study.

Authors:  Toru Okura; Brenda L Plassman; David C Steffens; David J Llewellyn; Guy G Potter; Kenneth M Langa
Journal:  J Am Geriatr Soc       Date:  2010-01-26       Impact factor: 5.562

3.  Behavioral symptoms of dementia: a dyadic effect of caregivers' stress process?

Authors:  Judy L M Campbell; Meredeth A Rowe; Michael Marsiske
Journal:  Res Gerontol Nurs       Date:  2010-09-30       Impact factor: 1.571

4.  Prescribing activities that engage passive residents. An innovative method.

Authors:  Ann Kolanowski; Linda Buettner
Journal:  J Gerontol Nurs       Date:  2008-01       Impact factor: 1.254

5.  Accounting for functional loss in Alzheimer's disease and dementia with Lewy bodies: beyond cognition.

Authors:  Joanne M Hamilton; David P Salmon; Rema Raman; Lawrence A Hansen; Eliezer Masliah; Guerry M Peavy; Douglas Galasko
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

6.  Vascular risk factors and neuropsychiatric symptoms in Alzheimer's disease: the Cache County Study.

Authors:  Martin Steinberg; Kyle Hess; Chris Corcoran; Michelle M Mielke; Maria Norton; John Breitner; Robert Green; Jeannie Leoutsakos; Kathleen Welsh-Bohmer; Constantine Lyketsos; Joann Tschanz
Journal:  Int J Geriatr Psychiatry       Date:  2013-05-17       Impact factor: 3.485

7.  Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum.

Authors:  Lauren P Wadsworth; Natacha Lorius; Nancy J Donovan; Joseph J Locascio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Gad A Marshall
Journal:  Dement Geriatr Cogn Disord       Date:  2012-08-28       Impact factor: 2.959

8.  Recreational Activities to Reduce Behavioural Symptoms in Dementia.

Authors:  Ann Kolanowski; Donna M Fick; Linda Buettner
Journal:  Geriatr Aging       Date:  2009-01-01

Review 9.  Behavioral symptoms related to cognitive impairment.

Authors:  Carol Dillon; Cecilia M Serrano; Diego Castro; Patricio Perez Leguizamón; Silvina L Heisecke; Fernando E Taragano
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-19       Impact factor: 2.570

10.  The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.

Authors:  George T Grossberg; Facundo Manes; Ricardo F Allegri; Luis Miguel Gutiérrez-Robledo; Sergio Gloger; Lei Xie; X Daniel Jia; Vojislav Pejović; Michael L Miller; James L Perhach; Stephen M Graham
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.